Myelodysplastic Syndrome (MDS)
We recommend
![lékařská studie](https://www.prolekare.cz/media/cache/resolve/article_list_item_large/media/image/5bb419c4d24ec76a127b9085bbe20f3e.jpg)
Efficacy of Luspatercept in 1st Line Treatment of Anemia Due to Low-Risk Myelodysplastic Syndrome
A planned interim analysis of the COMMANDS study showed a greater benefit of the innovative treatment with luspatercept compared to the established treatment with epoetin alfa in patients with anemia due to low-risk myelodysplastic syndrome (MDS) and untreated with erythropoiesis-stimulating agents (ESA). The results were published in June 2023 in the journal Lancet.
![transfuzní terapie](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/b0d2f7ad45b9eb16ea7c7a2e2958e38e.jpg)
Long-term Benefit of Luspatercept Therapy – Fresh Data from the MEDALIST Study
The goal of therapy for low-risk myelodysplastic syndrome (MDS) is to compensate for anemia,…
![starší muž aktivita](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/d27b99278cca2baf7148a678083caa05.jpg)
How Does Myelodysplastic Syndrome Affect Patients' Quality of Life?
Myelodysplastic syndrome (MDS) is a heterogeneous group of disorders of hematopoietic stem cells…
Articles on this topic
![anemia](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/556e51b1da39b5a611d3474314f6e21d.jpg)
Treatment of Low-Risk MDS According to NCCN Recommendations Version 1.2023
The latest recommendations from the American National Comprehensive Cancer Network (NCCN) for…
![Anemia therapy](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/375bcbb91cf9c3486703ed4266a8be93.jpg)
ESMO Recommendations for the Treatment of Low-Risk Myelodysplastic Syndrome
The priority in the treatment of low-risk myelodysplastic syndrome (MDS) is managing…
![analýza lékař](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/5e8895c6e79e03d7e68a5553a44ee666.jpg)
Effect of Luspatercept Treatment in Patients with MDS/MPN-RS-T
The presented post hoc analysis of the MEDALIST study demonstrates the effect and good…
![lékeřská doporučení](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/882f889a160328239ee63463b016b3cf.jpg)
Diagnosing Myelodysplastic Syndrome According to MDS Europe
In 2021, the European Hematology Association (EHA) endorsed the recommendations of the MDS…
![myelodysplastický syndrom3](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/313b31852379d301ff1394e276fcc99b.jpg)
Journal articles Role of the transforming growth factor (TGF)-β signal pathway in haematopoiesis and studies of new inhibitors of this pathway in the treatment of lower-risk myelodysplastic syndrome
Subscribe
Conferences news
Go to records
Most read on this topic
- Promising treatment modalities in the therapy of myelodysplastic syndromes
- Role of the transforming growth factor (TGF)-β signal pathway in haematopoiesis and studies of new inhibitors of this pathway in the treatment of lower-risk myelodysplastic syndrome
- Treatment strategies for myelodysplastic syndrome in 2021
- Diagnosing Myelodysplastic Syndrome According to MDS Europe
- ESMO Recommendations for the Treatment of Low-Risk Myelodysplastic Syndrome
- How Does Myelodysplastic Syndrome Affect Patients' Quality of Life?
Journal on this topic
Related topic